Clinical Trial: IL-15 Enhanced NK Cell Therapy for Solid Tumors

U.S., June 3 -- ClinicalTrials.gov registry received information related to the study (NCT07621471) titled 'IL-15 Enhanced NK Cell Therapy for Solid Tumors' on May 21.

Brief Summary: A single-arm, Phase 1 study evaluating safety, tolerability, and preliminary efficacy of IL-15 enhanced engineered NK cells in patients with refractory relapsed or metastatic solid tumors.

Study Start Date: July 01

Study Type: INTERVENTIONAL

Condition: Solid Tumors Metastatic Cancer

Intervention: DRUG: IL-15 enhanced engineered NK cells

Genetically engineered NK cells expressing IL-15. Administered intravenously. See protocol for dose details.

BIOLOGICAL: IL-15 Enhanced Engineered NK Cells

Genetically engineered NK cells expressing IL-15

Recruitment ...